156 results about "Gastrointestinal fluids" patented technology

The invention discloses an oxygen-containing heterocyclic compound salt, and a crystal form and application thereof. The oxygen-containing heterocyclic compound salt disclosed by the invention has a structure as shown in a formula II. The oxygen-containing heterocyclic compound salt and the crystal form thereof provided by the invention have one or more improved characteristics, which are represented by extremely high water solubility, and high dissolution rate and high solubility in physiological related medium simulated gastrointestinal fluid, so that the stability of the oxygen-containing heterocyclic compound under an oxidation condition is remarkably improved, and the stability of the oxygen-containing heterocyclic compound is improved. Low hygroscopicity and good crystal form stability are achieved, and oral absorption and long-term storage of the medicine are facilitated; and the preparation method is simple and suitable for industrial production. # imgabs0 #

Provided is an antibacterial peptide having an amino acid sequence X1KRFKKFFX2KLKKWV-NH2, wherein X1 is selected from any one or of amino acids A, C, D, E, F, G, H, K, L, N, M, P, Q, R, S, I, V, W, Y, and T or is absent; and X2 is an amino acid having an aromatic side chain or an amino acid having an alkaline side chain. In view of defects such as poor gastrointestinal fluid stability of antibacterial peptides in the prior art, a brand-new sequence design scheme and preparation method for an antibacterial peptide are provided. By means of a complete or partial D-amino acid substitution or structural derivatization of a peptide sequence, a series of antimicrobial peptides having stronger antibacterial activity and gastrointestinal stability as compared with the prior art are obtained, such that the antibacterial peptides have a wider application range and higher development potential value.

The invention discloses pediococcus acidilactici NDF12 and application thereof, the pediococcus acidilactici NDF12 is preserved in Guangdong Microbial Culture Collection Center on January 8, 2025, is called GDMCC for short, and the preservation number is GDMCC NO: 65732. The invention further discloses a preparation method of the pediococcus acidilactici NDF12. The strain is derived from Chinese local traditional dairy products, phenotype and genotype safety evaluation proves that the strain is safe and non-toxic, has excellent fermentation characteristics and probiotic characteristics, and can be used as a leavening agent for producing yoghourt. The bacterial strain also has gastrointestinal fluid endurance capacity, adhesion capacity, bacteriostatic activity, antioxidant activity, cholesterol lowering activity and blood sugar lowering activity, and has great application prospects in the fields of foods, medicines, feeds and the like.

The invention relates to the technical field of antibacterial drugs, in particular to an antibacterial peptide which has an amino acid sequence X1KRFKKFFX2KLKKWV-NH2, in which X1 is selected from any one or deletion of amino acids A, C, D, E, F, G, H, K, L, N, M, P, Q, R, S, I, V, W, Y and T; and X2 represents an amino acid having an aromatic side chain or an amino acid having a basic side chain. Aiming at the defects of poor gastrointestinal fluid stability and the like of the antibacterial peptide in the prior art, the invention provides a brand new antibacterial peptide sequence design scheme and a preparation method thereof, and the peptide sequence is subjected to full D-type amino acid or partial D-type amino acid replacement or structure derivation; compared with the prior art, a series of antibacterial peptides with higher antibacterial activity and gastrointestinal fluid stability are obtained, so that the antibacterial peptides have wider application range and higher potential development value.

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention discloses bifidobacterium lactis BA-C44 and application of the bifidobacterium lactis BA-C44 in relieving ulcerative colitis symptoms, the bifidobacterium lactis BA-C44 is preserved in the China Center for Type Culture Collection on December 04, 2023, and the preservation number is CCTCC NO: M 2023447. A product prepared from the bifidobacterium lactis BA-C44 disclosed by the invention has the beneficial effect of relieving symptoms of ulcerative colitis. Besides, the bifidobacterium lactis BA-C44 has good temperature tolerance and gastrointestinal fluid tolerance, is convenient for storage of commercial products after preparation, is easier to survive in intestines and stomach, and achieves the purpose of relieving symptoms of ulcerative colitis, so that the bifidobacterium lactis BA-C44 has a good application prospect.

The invention discloses a fermentation process and a preparation of lactobacillus reuteri L-01, and belongs to the field of microorganism preparation.After artificial domestication, bile salt tolerance of the lactobacillus reuteri L-01 is enhanced, the lactobacillus reuteri L-01 can be cultured in gastrointestinal fluid, and the survival rate of 98% or above can still be kept for a long time; the lactobacillus reuteri L-01 disclosed by the invention can play an excellent probiotic function, is beneficial to improving the balance of intestinal flora, has an inhibiting effect on pathogenic bacteria, and reduces the prevalence rate. Besides, after the components of the culture medium are optimized, the domesticated lactobacillus reuteri L-01 also has a certain anti-oxidation effect and is rich in selenium, so that the use value of the lactobacillus reuteri L-01 is increased. The lactobacillus reuteri L-01 fermentation broth is obtained, after a protective agent is added, the more excellent probiotic effect can be guaranteed, the stability of the lactobacillus reuteri L-01 in processing application and transportation storage is enhanced, and the lactobacillus reuteri L-01 fermentation broth has a certain slow-release effect and has a longer acting effect.

The invention provides a plant lactobacillus YN-03, a product prepared from the plant lactobacillus YN-03 and application, and belongs to the technical field of biological medicine, the plant lactobacillus YN-03 is preserved in China Center for Type Culture Collection on October 22, 2024, and the preservation number is CCTCC NO: M 20242301; the name of Latin is Lactiplantibacillus plantarum YN-03, and the name of Latin is Lactiplantibacillus plantarum YN-03; the gene sequence of the 16srRNA of the phytobacterium plantarum YN-03 is as shown in SEQ ID NO. 1, and the phytobacterium plantarum YN-03 has good gastrointestinal fluid and cholate tolerance. According to the plant lactobacillus YN-03, the product prepared from the plant lactobacillus YN-03 and the application of the plant lactobacillus YN-03, the plant lactobacillus YN-03 has the characteristic of high yield of GABA (gamma-aminobutyric acid) and shows potential application value in the aspect of relieving anxiety and depression.

The invention discloses application of fermented lactobacillus mucus capable of prolonging life, resisting aging and resisting oxidation, and belongs to the technical field of functional strains. The preservation numbers of the lactobacillus mucus A21224 and the lactobacillus mucus A21227 are GDMCC No: 62958 and GDMCC No: 62962 respectively, and the lactobacillus mucus A21224, the lactobacillus mucus A21227 and the lactobacillus mucus A21227 are used for The two strains can remarkably prolong the service life of nematodes, have good antioxidant effect and heat stress resistant effect, can prolong the service life of the nematodes by 40% in a strong oxidation environment, and can prolong the service life of the nematodes by 28.57% under the stress of a thermal environment. In addition, the lactobacillus mucus A21224 and the lactobacillus mucus A21227 both show an excellent anti-aging effect in the late stage of the nematodes. Meanwhile, the two strains have certain gastrointestinal fluid-resistant and cholate-resistant effects, can be colonized in intestinal tracts, have no hemolysis phenomenon and are high in safety.

The invention discloses lactobacillus amyloliquefaciens FMNS13 and application thereof, and belongs to the technical field of probiotics. The invention provides a strain of lactobacillus amyloliquefaciens FMNS13, the strain has good endurance capacity to gastrointestinal fluid and inhibition capacity to pathogenic bacteria, and the strain and metabolites thereof also have good oxidation resistance, can be used for preparing antioxidant drugs and health care products, or can be used for preparing freeze-dried fruit and vegetable products, and has wide application. The invention also optimizes the freeze-drying protective agent of the lactobacillus amyloliquefaciens FMNS13, so that the survival rate of viable bacteria in the lactobacillus amyloliquefaciens FMNS13 freeze-dried powder prepared by using the freeze-drying protective agent can reach 89.72%.

The invention discloses a Lactobacillus buchneri strain with high yield of gamma-aminobutyric acid and application of the Lactobacillus buchneri strain in preparation of nutritional and healthy fruit and vegetable juice. The strain is Lactobacillus buchneri GM3, and is preserved in the Guangdong Microbial Culture Collection Center on January 9, 2025, and the preservation number of the strain is GDMCC No: 65737. The invention further discloses a preparation method of the Lactobacillus buchneri strain. The strain not only has the capacity of producing gamma-aminobutyric acid at high yield, but also has good acid resistance, cholate resistance and gastrointestinal fluid resistance, and is very suitable for fermentation production of fermented fruit and vegetable juice. The contents of gamma-aminobutyric acid and flavonoid substances in fruit and vegetable juice fermented by the strain are greatly increased, and the nutritional value of the fruit juice is remarkably increased; moreover, the contents of alkaloid substances and total sugar are remarkably reduced, so that the tea is healthier, and the flavor is better and more unique. The Lactobacillus buchneri GM3 is a safe lactic acid bacterium, and the Lactobacillus buchneri GM3 and the technology for producing fruit and vegetable juice through fermentation of the Lactobacillus buchneri GM3 have very good application value and market prospect.

The invention discloses a shell-core double-layer gel ball with a targeted delivery function and a preparation method and application thereof, belongs to the technical field of shell-core gels, and provides the preparation method of the shell-core double-layer gel ball with the targeted delivery function, and the preparation method comprises the following steps: mixing a polysaccharide aqueous solution and a protein aqueous solution in an isovolumetric manner to obtain a composite gel precursor solution, and performing water bath treatment to obtain the shell-core double-layer gel ball with the targeted delivery function. Dropwise adding the thermal copolymerization product into a calcium chloride aqueous solution, curing to obtain a single cross-linked gel ball, immersing the single cross-linked gel ball into a tannic acid aqueous solution, and curing to obtain a shell-core double-layer gel ball. The polysaccharide is used as a core skeleton, and the protein and tannic acid compound is used for filling outer layer pores to form a shell with a compact double-penetrating network structure, so that the barrier property on oxygen and gastrointestinal fluid is remarkably improved, and the storage stability and the in-vivo colonization effect can be improved.

The invention relates to the technical field of biological medicine, and discloses bifidobacterium adolescentis YF-01 and application thereof in fermented milk. The bifidobacterium adolescentis YF-01 is separated from adult excrement and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20251308. Experiments prove that the bifidobacterium adolescentis YF-01 has good gastrointestinal fluid tolerance, the survival rate of the bifidobacterium adolescentis YF-01 can reach 90.1% after simulated gastric fluid treatment for 3 h, and the survival rate of the bifidobacterium adolescentis YF-01 can reach 72% after simulated intestinal fluid treatment for 4 h The strain has the self-aggregation rate of 88.83% and the hydrophobicity of 79.41%, has remarkable scavenging capacity on DPPH free radicals and hydroxyl free radicals, shows good antioxidant activity and adhesion capacity, and provides a theoretical basis for application of the strain in fermented milk. The strain and metabolites thereof can be used for preparing food, medicines or health care products capable of regulating intestinal flora and enhancing oxidation resistance, and have remarkable application potential in development of functional fermented milk products.

The invention discloses a plant lactobacillus HUCF11 strain and application thereof in preparation of a medicine for relieving ferroptosis, and belongs to the technical field of functional microorganisms. In order to excavate a microecological preparation for treating ferroptosis-related diseases, the invention separates a plant lactobacillus HUCF11 strain, and the strain HUCF11 strain is proved to have better tolerance and no toxicity to artificial gastrointestinal fluid through a simulated gastrointestinal fluid experiment and a toxicity evaluation experiment; the establishment of a drosophila ferroptosis model proves that the following symptoms caused by ferroptosis can be improved by taking the strain HUCF11: degeneration of action ability, shortening of sleep duration, anxiety and unease, reduction of DPPH free radical scavenging ability and antioxidant ability and reduction of glutathione level; the expression of an intestinal tissue ferroptosis related gene gpx4 is abnormal; and the intestinal flora structure is disordered. The strain HUCF11 provided by the invention can be used for preparing medicines for relieving ferroptosis, and a new way is opened up for relieving ferroptosis.

The invention provides fermented lactobacillus mucus BL-SWN1 and application thereof, the fermented lactobacillus mucus BL-SWN1 is screened from naturally fermented soybean clear water, is preserved in China General Microbiological Culture Collection Center (CGMCC) on January 6, 2025, is named as Limosilicilla fermentum in taxonomy, has a preservation number of CGMCC No.33307, and belongs to the technical field of microorganisms. The lactobacillus mucus BL-SWN1 has good acid production capacity, gastrointestinal fluid and cholate tolerance, bacteriostatic activity and nitrite degradation capacity, the pH value of a culture medium can be reduced to about 4.3 within 24 h of culture, and the nitrite degradation rate reaches 95% or above. The fermentation lactobacillus mucus BL-SWN1 can be applied to vegetable fermentation products such as pickled Chinese cabbages and pickled vegetables, can also be suitable for the fermentation process of dairy products and meat products, has a wide application prospect in the food industry, and particularly has remarkable advantages in the aspect of development of healthy fermentation foods.

This invention discloses a probiotic microcapsule and its preparation method, belonging to the field of microcapsule preparation technology. The preparation method includes the following steps: (1) dissolving Sophora japonica extract in water, stirring, adding sodium alginate, and stirring again to obtain a wall material solution; (2) centrifuging and washing the activated probiotics, preparing a bacterial suspension, mixing it with the wall material solution obtained in step (1), stirring, and obtaining a wall material bacterial suspension; (3) adding the wall material bacterial suspension obtained in step (2) to a calcium chloride solution and letting it stand, then adding the formed gel to a chitosan solution, stirring, washing, and obtaining the final product. The preparation process of this invention is simple and convenient, and the raw materials are inexpensive and easy to obtain, which can effectively reduce the production cost of microcapsules, facilitate large-scale industrial production and application promotion, effectively improve the biocompatibility, biodegradability, mechanical strength and encapsulation rate of microcapsules, and enhance the storage stability and resistance to gastrointestinal fluid stress of microcapsules.

The invention discloses lactobacillus mucilaginosus and application thereof, and belongs to the technical field of microbial fermentation. The invention provides a lactobacillus mucus WX20 which is preserved in the Guangdong Microbial Culture Collection Center on September 12, 2024, and the preservation number of the lactobacillus mucus WX20 is GDMCC No: 65083. The lactobacillus mucus WX20 has the advantages that the lactobacillus mucus WX20 is preserved in the Guangdong Microbial Culture Collection Center on September 12, 2024; the strain obtained by screening can effectively degrade inosine and guanosine and inhibit the activity of xanthine oxidase, and has good tolerance in a simulated gastrointestinal fluid environment. When the strain is used for fermenting the leaf mustard, the fermentation period of the fermented leaf mustard can be shortened, a product prepared by utilizing the strain has the activity of degrading inosine and guanosine and inhibiting xanthine oxidase, a microbial inoculum and pickles can remarkably reduce the blood uric acid level of a mouse with hyperuricemia, and the strain has considerable application potential and high market value.

The invention relates to a plant lactobacillus JN-7, bacterial powder, a preparation method, a probiotic composition and application thereof. According to the application, a new plant lactobacillus strain is obtained through screening, the new plant lactobacillus strain is named as plant lactobacillus JN-7, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.30605. Basic characteristic analysis (growth curve, acid resistance, cholate resistance and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolysis capability, toxin production capability and cytotoxicity), adhesiveness evaluation, anti-inflammatory action evaluation, production performance evaluation (fermentation yield and freeze-drying yield) and stability test (accelerated storage stability test) of the strain are carried out; it is found that the plant lactobacillus JN-7 is a safe strain and has excellent production performance, high stability and an anti-inflammatory effect. The bacterial powder produced by the bacterial strain can keep stable and active for a long time.

The invention discloses eggshell membrane polypeptide with DPP-IV enzyme inhibitory activity and application of the eggshell membrane polypeptide in blood glucose regulation, and belongs to the technical field of biology. The amino acid sequence of the eggshell membrane polypeptide is as shown in SEQ ID NO. 1. According to the invention, a high-activity polypeptide Ala-Pro-Ser-Pro-Trp-Glu is separated and identified from an eggshell membrane, the polypeptide is proved to have certain DPP-IV inhibition ability both in cells and outside cells, the stable DPP-IV inhibition activity is maintained in an in-vitro simulated gastrointestinal fluid environment, and a theoretical basis is provided for research and development of novel diabetes drugs.

The invention provides a lactobacillus plantarum strain A21337 with the functions of inhibiting bacteria and secreting 5-hydroxytryptamine, a probiotic agent of the lactobacillus plantarum strain A21337 and application of the lactobacillus plantarum strain A21337, and belongs to the technical field of functional microorganisms. The invention provides application of phytobacterium plantarum or a microbial agent containing the phytobacterium plantarum in preparation of a product resisting pathogenic bacteria and / or rich in 5-hydroxytryptamine. According to the invention, a plant lactobacillus strain A21337 is separated from intestinal feces of healthy 100-year old people in Guangxi province, has the characteristics of secreting 5-hydroxytryptamine and inhibiting pathogenic bacteria, and has good tolerance to gastrointestinal fluid. Therefore, the strain A21337 or the probiotic agent containing the strain A21337 provides a new means for preparing a product which is resistant to pathogenic bacteria and / or rich in 5-hydroxytryptamine.

According to the invention, the traditional fermented koumiss in Xinjiang is collected, two novel multifunctional probiotic strains, namely, the lactobacillus plantarum SR6 GDMCC NO.66817 strain and the enterococcus faecalis SM5 GDMCC NO.66816 strain with good compatibility are separated and screened out, and the two strains have the characteristics of reducing blood fat, reducing cholesterol, removing triglyceride, resisting oxidation and antagonizing pathogenic bacteria, and have the characteristics of good cholate and gastrointestinal tract tolerance, high survival rate and good safety. The growth characteristics and compatibility of the two strains are improved; the inhibition rate of cholesterol esterase and pancreatic lipase; the method comprises the following steps: evaluating the triglyceride removal rate, antioxidant activity, pathogenic bacterium resistance, artificially simulated gastrointestinal fluid tolerance, strain drug resistance and safety, compounding lactobacillus plantarum SR6 and enterococcus faecalis SM5 strains according to a ratio of 1: 1 to prepare a freeze-dried bacterial agent, and keeping good survival rate (pgt; 0.05) and functional characteristics, the strain can be used as a functional direct vat set starter and is directly applied to production of fermented dairy products, and the biological activity of food is improved.

The invention discloses a strain of Bacteroides ovatus L2 and application of the strain of Bacteroides ovatus L2 in a product for preventing and treating vomitoxin toxicity. The strain is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC.No: 67205, and the preservation date is November 4, 2025. The strain is separated and purified from a healthy adult excrement sample, has the characteristics of good acid resistance, cholate resistance, gastrointestinal fluid resistance and the like, and is free of hemolysis and good in safety. The strain can effectively relieve the toxic effect induced by vomitoxin, mainly inhibits inflammatory factors and promotes expression of intestinal barrier functional proteins, can be applied to products of microecologics for preventing and treating DON toxicity, and has a good application prospect.

A process for removing Pb2+ ions from fluids, such as gastrointestinal fluids is described. The process involves contacting gastrointestinal fluid with a particulate metal titanate ion exchanger represented by the empirical formula: AmTixMyOz where A is an exchangeable cation selected from the group consisting of potassium ion, sodium ion, lithium ion, calcium ion, magnesium ion, hydronium ion, and mixtures thereof, and M is optionally at least one framework metal selected from niobium (5+), zirconium (4+), tin (4+), iron (3+), iron (2+), cobalt (2+), and manganese (2+). The particulate metal titanate ion exchangers of the present disclosure are synthesized in the presence of complexing agents, including at least one multihydroxyl-containing complexing agent (MHCA), which facilitate metal transport and incorporation while imparting beneficial properties such as large aggregate size, well-behaved particle size distribution, and macroporosity.

Embodiments of devices and methods for sampling gastrointestinal fluids and assessing gastrointestinal function using a device comprising a sampling tube are provided.

The invention belongs to the technical field of microorganisms, and relates to a bifidobacterium breve strain capable of relieving constipation, the strain is bifidobacterium breve Bb-PG-14, the classification name of the strain is Bifidobacterium breve, the preservation number is CGMCC No.31861, the preservation time is September 4, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, and the preservation number is CGMCC No.31861. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain is separated and purified from excrement of healthy babies, has relatively strong acid resistance, alkali resistance, cholate resistance and artificial simulated gastrointestinal fluid tolerance, and has the characteristics of probiotics.

The invention belongs to the technical field of surgical instruments, and particularly relates to a gastrointestinal fluid decompression device for gastrointestinal surgery, which comprises a shell, a negative pressure assembly, a cleaning assembly and a switching mechanism, the switching mechanism drives the negative pressure assembly and the cleaning assembly to be in butt joint with the butt joint opening in a negative pressure mode and a cleaning mode correspondingly and form negative pressure and release cleaning liquid in a pipeline connected with the butt joint opening correspondingly, the negative pressure assembly is a negative pressure peripheral pump, the cleaning assembly is a liquid conveying screw pump, the switching mechanism comprises a gear ring and a motor, the gear ring is rotationally arranged in the shell, and the motor is arranged in the shell. A transmission gear is arranged on an output shaft of the motor and meshed with the outer side of the gear ring, the inner side of the gear ring is meshed with a rotating shaft of the negative-pressure peripheral pump and a transmission rod of the liquid conveying screw pump, and positive and negative rotation of the gear ring is used for driving the negative-pressure peripheral pump and the liquid conveying screw pump to be switched to the butt joint position of the butt joint opening and driving the rotating shaft and the transmission rod to rotate. The negative pressure can be provided and the pipeline can be cleaned by switching positions.

The application discloses a plant lactobacillus strain and application thereof, and belongs to the technical field of microorganisms. The preservation number of the strain is CGMCC No. 33864. The strain has good tolerance to gastrointestinal juice and bile salts and has no hemolytic activity. Concentrated cell-free supernatant prepared from the strain can inhibit salmonella, including inhibiting the growth of salmonella, killing bacteria, inhibiting or removing biofilm. Animal experiments show that the strain and the concentrated cell-free supernatant thereof can prevent salmonella infection, alleviate weight loss caused by infection, maintain intestinal barrier integrity, reduce the level of pro-inflammatory factors, alleviate tissue damage, improve the expression of colon tight junction proteins and mucin, promote the generation of short-chain fatty acids, and restore the intestinal flora structure. The application further provides a microbial preparation containing the strain and / or the concentrated cell-free supernatant thereof. The strain and the microbial preparation can be used for preparing products for resisting salmonella, preventing salmonella infection or improving intestinal health.

This invention discloses a method for preparing piperine starch microcapsules with sustained-release properties, belonging to the field of food processing technology. Using piperine as the core material, oleic acid as the oil phase carrier, and PG 2000 type octenyl succinate starch ester as the wall material, sustained-release piperine microcapsules are prepared through oil phase preparation, aqueous phase preparation, high-speed shearing, high-pressure homogenization, and spray drying. The microcapsules prepared by this invention have high encapsulation efficiency, small and uniformly distributed reconstituted particle size, and a stable system that is not prone to sedimentation. This allows for the slow and continuous release of piperine in simulated gastrointestinal fluid, significantly improving its poor water solubility, low stability, and low bioavailability. The resulting product can be widely used in the food, health product, and pharmaceutical fields.

A plant lactobacillus JN9, a preparation, a probiotic composition and its use. The present application obtains a new plant lactobacillus JN9 through screening, and the deposit number is: CCTCC NO: M 20241647. Through the basic characteristic analysis (growth curve, acid resistance, bile salt resistance, gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic ability, toxin production ability, cytotoxicity, ability to produce bioamines), adhesion evaluation, GABA production evaluation, alcohol tolerance and acetaldehyde dehydrogenase production ability evaluation of the strain, it is found that it is a safe strain with excellent GABA production performance, high alcohol tolerance and high acetaldehyde dehydrogenase enzyme activity. It can be used to improve mood such as relieving stress, anti-depression and improving the body's sleep quality, lowering blood pressure, anti-diabetes, anti-cancer, anti-oxidation, anti-inflammatory, anti-microbial, anti-allergic, and enhancing alcohol tolerance during drinking and relieving discomfort after drinking.